Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 350 versus OMNIPAQUE 70.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 350 versus OMNIPAQUE 70.
OMNIPAQUE 350 vs OMNIPAQUE 70
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque agent: iodine-containing contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. Non-ionic, low-osmolar agent.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
1-2 mL/kg IV up to 150 mL for CT; 30-50 mL IV for DSA; max 350 mL per procedure.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. May be prolonged in renal impairment.
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Primarily renal excretion via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<1%).
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent